Abstract

CRISPR-Cas systems are emerging as pivotal diagnostic tools for infectious diseases, providing rapid, accurate, and cost-effective pathogen detection. These advanced biosensing platforms utilize high sensitivity and specificity, making them ideal for point-of-care applications. Significant developments focus on creating user-friendly, portable solutions that operate effectively without extensive laboratory infrastructure. This facilitates quick, on-site identification of diverse pathogens, including SARS-CoV-2, thereby addressing critical global health needs by bridging diagnostic gaps and enhancing accessibility, especially in resource-constrained environments.